JP7899159B2 - 抗血小板薬およびその使用 - Google Patents
抗血小板薬およびその使用Info
- Publication number
- JP7899159B2 JP7899159B2 JP2023506150A JP2023506150A JP7899159B2 JP 7899159 B2 JP7899159 B2 JP 7899159B2 JP 2023506150 A JP2023506150 A JP 2023506150A JP 2023506150 A JP2023506150 A JP 2023506150A JP 7899159 B2 JP7899159 B2 JP 7899159B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- approximately
- compounds
- saturated
- disclosure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/105513 | 2020-07-29 | ||
| CN2020105513 | 2020-07-29 | ||
| PCT/CN2021/108875 WO2022022559A1 (en) | 2020-07-29 | 2021-07-28 | Antiplatelet drugs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535815A JP2023535815A (ja) | 2023-08-21 |
| JP2023535815A5 JP2023535815A5 (cg-RX-API-DMAC7.html) | 2024-08-13 |
| JP7899159B2 true JP7899159B2 (ja) | 2026-08-03 |
Family
ID=80037185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023506150A Active JP7899159B2 (ja) | 2020-07-29 | 2021-07-28 | 抗血小板薬およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12410132B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4342532B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7899159B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102906376B1 (cg-RX-API-DMAC7.html) |
| CN (4) | CN119552111B (cg-RX-API-DMAC7.html) |
| AR (1) | AR123078A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021317436A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023001595A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186645A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3046366T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299979A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001232A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI925859B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022022559A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202339745A (zh) * | 2022-01-28 | 2023-10-16 | 大陸商上海柯君醫藥科技有限公司 | 抗血小板藥物的藥物組合物及其用途 |
| CN116813532B (zh) * | 2023-06-29 | 2026-05-15 | 上海柯君医药科技有限公司 | 一种哌啶化合物的制备方法 |
| WO2025108307A1 (zh) | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用 |
| WO2025108300A1 (zh) | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用 |
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119176829B (zh) * | 2024-11-26 | 2025-04-15 | 上海柯君医药科技有限公司 | 一种哌啶环化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
| CN119371453A (zh) * | 2024-12-30 | 2025-01-28 | 上海柯君医药科技有限公司 | 一种抗血小板药物中间体的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106554368A (zh) | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554303A (zh) | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ334389A (en) * | 1996-08-28 | 2001-05-25 | Ube Industries | Cyclic amine derivatives |
| CA2570048A1 (en) * | 2004-07-07 | 2006-01-12 | Medicure International Inc. | Combination therapies employing platelet aggregation drugs |
| CN104379589A (zh) * | 2012-05-07 | 2015-02-25 | 塞利克斯比奥私人有限公司 | 抗血小板药剂的前药 |
| CA2880898A1 (en) * | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
| CN103626694A (zh) * | 2012-08-29 | 2014-03-12 | 中国药科大学 | 不饱和环胺衍生物、其制备方法及其医药用途 |
| NO2721243T3 (cg-RX-API-DMAC7.html) * | 2014-10-01 | 2018-10-20 | ||
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
-
2021
- 2021-07-28 CN CN202411716601.2A patent/CN119552111B/zh active Active
- 2021-07-28 MX MX2023001232A patent/MX2023001232A/es unknown
- 2021-07-28 EP EP24156405.3A patent/EP4342532B1/en active Active
- 2021-07-28 KR KR1020257016343A patent/KR102906376B1/ko active Active
- 2021-07-28 IL IL299979A patent/IL299979A/en unknown
- 2021-07-28 ES ES24156405T patent/ES3046366T3/es active Active
- 2021-07-28 CA CA3186645A patent/CA3186645A1/en active Pending
- 2021-07-28 CN CN202410873004.4A patent/CN119033782B/zh active Active
- 2021-07-28 BR BR112023001595A patent/BR112023001595A2/pt unknown
- 2021-07-28 CN CN202311275197.5A patent/CN117343000A/zh active Pending
- 2021-07-28 WO PCT/CN2021/108875 patent/WO2022022559A1/en not_active Ceased
- 2021-07-28 JP JP2023506150A patent/JP7899159B2/ja active Active
- 2021-07-28 US US18/018,576 patent/US12410132B2/en active Active
- 2021-07-28 EP EP21851193.9A patent/EP4188935A4/en active Pending
- 2021-07-28 KR KR1020237007048A patent/KR20230047425A/ko not_active Ceased
- 2021-07-28 CN CN202180058245.8A patent/CN116194459A/zh active Pending
- 2021-07-28 AU AU2021317436A patent/AU2021317436A1/en active Pending
- 2021-07-29 AR ARP210102107A patent/AR123078A1/es unknown
- 2021-07-29 TW TW110127818A patent/TWI925859B/zh active
-
2025
- 2025-07-08 US US19/262,108 patent/US20250333382A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106554368A (zh) | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554303A (zh) | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
Non-Patent Citations (12)
| Title |
|---|
| BLUET, Guillaume et al.,"Synthesis of the stabilized active metabolite of clopidogrel",Tetrahedron,2014年,Vol. 70,No. 25,p. 3893-3900,DOI: 10.1016/j.tet.2014.04.037 |
| DANSETTE, Patrick M. et al.,"Metabolic Activation of Prasugrel: Nature of the Two Competitive Pathways Resulting in the Opening of Its Thiophene Ring",Chemical Research in Toxicology,2012年,Vol. 25,No. 5,p. 1058-1065,DOI: 10.1021/tx3000279 |
| DELAVENNE, Xavier et al.,"Ultra‐performance LC MS/MS method for quantification of clopidogrel active metabolite",Journal of Separation Science,2010年,Vol. 33,No. 13,p. 1968-1972,DOI: 10.1002/jssc.201000115 |
| FARID, Nagy A. et al.,"Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry",Rapid Communications in Mass Spectrometry,2007年,Vol. 21,No. 2,p. 169-179,DOI: 10.1002/rcm.2813 |
| FURLONG, Michael T. et al.,"A validated HPLCMS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: Application to a clinical pharmacokinetic study",Journal of Chromatography B,2013年,Vol. 926,p. 36-41,DOI: 10.1016/j.jchromb.2013.02.031 |
| HAGIHARA, Katsunobu et al.,"Glutaredoxin Is Involved in the Formation of the Pharmacologically Active Metabolite of Clopidogrel from Its GSH Conjugate",Drug Metabolism and Disposition,Vol. 40,No. 9,2012年,p. 1854-1859,DOI: 10.1124/dmd.112.045914 |
| LIU, Cai et al.,"Development and validation of a sensitive and rapid UHPLCMS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma",Journal of Pharmaceutical and Biomedical Analysis,2018年,Vol. 149,p. 394-402,DOI: 10.1016/j.jpba.2017.11.019 |
| Liu, Shuai-bing et al.,Determination of clopidogrel and its metabolites in plasma by UPLC-MS/MS and application in pharmacokinetic study,Yaowu Fenxi Zazhi,2015年,Vol. 35,No. 1,p. 56-63 |
| SHAW, Scott A. et al.,"Synthesis of Biologically Active Piperidine Metabolites of Clopidogrel: Determination of Structure and Analyte Development",The Journal of Organic Chemistry,2015年,Vol. 80,No. 14,p. 7019-7032,DOI: 10.1021/acs.joc.5b00632 |
| TAKAHASHI, Makoto et al.,"Quantitative determination of clopidogrel active metabolite in human plasma by LCMS/MS",Journal of Pharmaceutical and Biomedical Analysis,2008年,Vol. 48,No. 4,p. 1219-1224,DOI: 10.1016/j.jpba.2008.08.020 |
| Tian, Xi et al.,Determination of clopidogrel and its active metabolite in human plasma by LC-MS/MS,Zhongguo Yiyao Gongye Zazhi,2016年,Vol. 47,No. 2,p. 202-206,DOI: 10.16522/j.cnki.cjph.2016.02.016 |
| 内田哲郎ら,(5-Methyl-2-oxo-1,3-dioxol-4-yl) methyl Thiamine Sulfideの合成と性状,薬学雑誌,2006年,Vol. 126,No. 3,p. 179-186,DOI: 10.1248/yakushi.126.179 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116194459A (zh) | 2023-05-30 |
| KR20230047425A (ko) | 2023-04-07 |
| IL299979A (en) | 2023-03-01 |
| TW202214609A (zh) | 2022-04-16 |
| CN119033782A (zh) | 2024-11-29 |
| TWI925859B (zh) | 2026-05-21 |
| KR20250073569A (ko) | 2025-05-27 |
| MX2023001232A (es) | 2023-05-15 |
| US20250333382A1 (en) | 2025-10-30 |
| EP4342532C0 (en) | 2025-09-03 |
| US20240279178A1 (en) | 2024-08-22 |
| AU2021317436A1 (en) | 2023-02-23 |
| ES3046366T3 (en) | 2025-12-01 |
| CN119552111A (zh) | 2025-03-04 |
| CA3186645A1 (en) | 2022-02-03 |
| EP4342532B1 (en) | 2025-09-03 |
| CN119552111B (zh) | 2026-01-02 |
| EP4188935A1 (en) | 2023-06-07 |
| KR102906376B1 (ko) | 2025-12-30 |
| AR123078A1 (es) | 2022-10-26 |
| WO2022022559A1 (en) | 2022-02-03 |
| CN119033782B (zh) | 2025-04-25 |
| US12410132B2 (en) | 2025-09-09 |
| EP4342532A3 (en) | 2024-07-17 |
| EP4188935A4 (en) | 2024-07-17 |
| EP4342532A2 (en) | 2024-03-27 |
| BR112023001595A2 (pt) | 2023-04-04 |
| CN117343000A (zh) | 2024-01-05 |
| JP2023535815A (ja) | 2023-08-21 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240726 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240801 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250617 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250612 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250916 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260408 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260623 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260722 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7899159 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |